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Abstract
Introduction Hypertesion is the leading cause of morbidity and mortality, worldwide, and its prevalence has been increasing 
in several countries, including Italy.
Aims To assess hypertension prevalence, awareness, treatment, and control in a real-world sample of adults with self-reported 
diabetes compared with nondiabetic individuals.
Methods Following the 2018 World Hypertension Day, a nationwide, cross-sectional epidemiological survey on cardiovascu-
lar risk factors (“Abbasso la Pressione!”) in 3956 Italian pharmacies enrolled 47217 self-presenting volunteers (≥ 18 years). 
Participants underwent standardized blood pressure (BP) measurements and answered a questionnaire on cardiovascular 
risk factors and lifestyle habits. Questions included if they had an established diagnosis of diabetes, hypertension or were 
on a BP medication. Hypertension prevalence was defined as systolic BP ≥ 140 and/or diastolic BP ≥ 90 mmHg. A double 
definition for hypertension control based on the recent European and US guidelines on hypertension was applied.
Results Diabetic individuals (N = 5695, 12%) had higher rates of hypertension prevalence (80% vs. 54.7%, p < 0.001), 
awareness (85.6% vs 77.3%, p < 0.001) and treatment (85.8% vs. 76.7%, p < 0.001), but lower hypertension control rates 
(36.1% vs. 39.6% according to the 2018 European guidelines, p < 0.001; 25.4% vs 30.8% according to the 2017 US guide-
lines, p < 0.001) than nondiabetics. Diabetic participants tended to be older, sedentary, overweight/obese, dyslipidemic men, 
with higher 10-years cardiovascular risk than nondiabetics (p < 0.001). Uncontrolled hypertension was associated with male 
gender, diabetes, body mass index, unhealthy lifestyle habits, and older age.
Conclusions Elevated hypertension awareness and treatment rates in diabetic adults do not translate into adequate BP con-
trol in the real world. Concomitant unfavorable metabolic features and unhealthy lifestyle habits might contribute to this 
observation.
Keywords Aspects of diabetes · Arterial hypertension · Awareness · Control · Population survey
1 Introduction
Hypertension is an independent risk factor for cardiovascular 
diseases (CVD) [1]. Its prevalence is estimated at around 
30% of the adult population in industrialized countries, but 
it becomes even more common in the presence of diabe-
tes mellitus [2]. The simultaneous presence of diabetes and 
hypertension accelerates the development of micro- and 
macrovascular complications and further increases cardio-
vascular risk by at least fourfold compared with the absence 
of these conditions [2].
In keeping with this, data from the Framingham Heart 
Study showed that individuals with concomitant diabetes 
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and hypertension exhibited higher rates of all-cause mor-
tality (32 against 20 for 1000 people-year, p < 0.001) and 
cardiovascular events (52 versus 31 for 1000 people-year; 
p < 0.001) than diabetic individuals with normal blood pres-
sure (BP), suggesting that the exceeding burden of disease in 
the former was largely attributable to hypertension [3]. The 
intensity of care and related costs for comorbid hyperten-
sion and diabetes are not additive: indeed, they exceed those 
related to the separate management of the diseases [4, 5].
In parallel, hypertension control rates remain globally 
unsatisfactory for the standard of high-quality hypertension 
programmes [6]. In fact, despite a substantial improvement 
compared with the 1980s, treatment coverage and control 
rates for hypertension have settled at best around 80% and 
60–70%, respectively, since mid-2000s [6–8]. Several physi-
opathological and management-related factors, including 
application and adherence to pharmacological and non-phar-
macological strategies for the management of hypertension, 
make adequate BP control achievement even more challeng-
ing in the presence of diabetes [9–12]. In consideration of 
the elevated socioeconomic burden and the relevant use of 
healthcare resources, the detection of hypertension and fac-
tors related to BP control among individuals with diabetes 
is a public health priority.
We analyzed data from a nationwide, cross-sectional 
epidemiological survey conducted in 3956 Italian pharma-
cies during the 2018 World Hypertension day to assess real-
world hypertension prevalence, awareness, treatment, and 
control rates among individuals with self-reported diabetes 
compared with nondiabetic participants.
2  Methods
2.1  Data Source
Abbasso la Pressione! (May 17–20, 2018) was a 4-days, 
nationwide, cross-sectional epidemiological Italian survey 
co-sponsored by the Italian Society of Hypertension (SIIA) 
in collaboration with the National Federation of Italian Phar-
macies (Federfarma) following the World Hypertension Day 
in 2018 [13]. It involved 3956 pharmacies (21% of total) 
throughout the national territory with the aim of estimat-
ing prevalence and awareness of modifiable/non-modifiable 
cardiovascular risk factors, with particular focus on hyper-
tension, among self-presented adult customers (≥ 18 years) 
who consented to participate. Participation was completely 
voluntary, and signed informed consent was obtained from 
each participant. The survey and related research fulfill the 
principles stated in the Declaration of Helsinki.
2.2  Data Collection
Self-presenting participants who consented to participate 
underwent 3 standardized BP measurements according to 
guidelines protocol [1] and answered a questionnaire on 
cardiovascular risk factors and lifestyle habits. BP was 
measured for each participant after 2 minutes rest, in sitting 
position, by trained pharmacists using an automated oscil-
lometric device, and the average of the second and third 
measurements was used for the analysis. The questionnaire 
included if they had an established diagnosis of diabetes 
(irrespective of diabetes type), hypertension, or were on a BP 
medication. Self-reported anthropometric data (age, height, 
weight) were expressed as numeric variables. Additional 
modifiable (smoking; sedentary lifestyle in terms of  < 30 
minutes/day of physical activity; hypercholesterolemia) and 
unmodifiable (gender; family history of CVD) cardiovascu-
lar risk factors, dietary habits (unlimited use of dietary salt; 
everyday consumption of fruit and vegetables), as well as 
the presence of established CVD and chronic kidney disease 
(CKD) were expressed as categorical data. BMI was calcu-
lated based on self-declared weight and height. The 10-year 
cardiovascular risk was derived according to guidelines [14]. 
Geographic provenance was recorded automatically.
2.3  Statistical Analysis
Diabetic status was defined as being diabetic or nondia-
betic based on self-reported information. BP was treated as 
both a numeric value (mmHg) and a categorical variable 
(i.e BP status, expressed as: controlled/uncontrolled hyper-
tension; and BP categories, expressed as: optimal, normal, 
or high normal BP, grade 1-2-3 hypertension, and isolated 
systolic hypertension) [15]. Based on the 2017 American 
College of Cardiology/American Heart Association (ACC/
AHA) Guidelines for the management of arterial hyperten-
sion [1], the diagnostic threshold for hypertension was BP 
≥ 140 and/or 90 mmHg, while the BP target was  < 130/80 
mmHg for both diabetic and nondiabetic participants. An 
additional definition of controlled hypertension was also 
tested, based on the 2018 European Society of Cardiology/
European Society of Hypertension (ESC/ESH) guidelines 
for the management of hypertension ( < 130/80 mmHg in 
treated participants  < 65 years, and  < 140/80 mmHg if 
≥ 65 years) [15]. Hypertension prevalence rate was defined 
based on measured BP values above the specified threshold 
among individuals not receiving antihypertensive medica-
tions, or as being on antihypertensive drugs. Hypertension 
awareness rate was defined as the proportion of participants 
with prevalent hypertension who reported having been diag-
nosed, while hypertension treatment rate was defined as the 
proportion of participants with prevalent hypertension who 
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were using medication to treat this condition. Hypertension 
control rate among individuals on antihypertensive treat-
ment was defined as having BP values below the previously 
specified target. Hypertension treatment and control rates 
and 95% confidence intervals (CI) were evaluated according 
to diabetic status, and the likelihood estimate for the differ-
ence between participants with and without diabetes was 
evaluated using Yates correction for continuity.
The age- and gender-adjusted odds ratio (OR) and relative 
95% CI for the association between diabetic status (depend-
ent variable) and hypertension (independent variable) was 
assessed by logistic regression. An additional model was 
fitted to investigate the association of uncontrolled hyperten-
sion (dependent variable) with selected risk factors (inde-
pendent covariates).
Differences in participants’ characteristics were evalu-
ated with unpaired t tests for continuous variables (mean ± 
standard deviation, SD) and χ2 tests for categorical variables 
(N, %). Statistical analyses were performed using R (v 4.0.2) 
[16]. Statistical significance was set at p < 0.05.
3  Results
3.1  General Characteristics of the Sample
Of 47217 participants enrolled in the project, 12.1% 
(N = 5695) had diabetes. Clinical and demographic charac-
teristics by diabetes status are summarized in Table 1.
Compared with nondiabetic participants, individuals with 
diabetes tended to be older, overweight/obese, dyslipidemic 
men, with greater prevalence of family/personal history of 
CVD/CKD, higher mean systolic BP (136.0 ± 18.4 mmHg 
versus 128.3 ± 17.8 mmHg, p < 0.001) and higher 10-year 
cardiovascular risk (Table 1). Diabetic individuals were 
more sedentary and were less likely to report a regular use 
of fruits/vegetables than nondiabetics. In parallel, they also 
Table 1  Demographic, clinical 
and lifestyle characteristics of 
survey participants with and 
without diabetes
Chi-squared test and Student’s t test are applied, as appropriate
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, CVD cardiovascular dis-
ease, CKD chronic kidney disease
Diabetic participants Nondiabetic participants p-value
N 5695 41,522
Men (%) 2794 (49.1) 15,820 (38.1) < 0.001
Age category, years (%) < 0.001
 < 35 135 (2.4) 3267 (7.9)
 35-44 249 (4.4) 4819 (11.6)
 45-64 1821 (32.0) 17,854 (43.0)
 ≥ 65 3490 (61.3) 15,582 (37.5)
 SBP, mmHg (mean, SD) 136.0 ± 18.4 128.3 ± 17.8 < 0.001
 DBP, mmHg (mean, SD) 76.8 ± 11.4 76.7 ± 10.7 0.366
BMI category (%) < 0.001
 Underweight 42 (0.7) 975 (2.3)
 Normal 1591 (27.9) 18,932 (45.6)
 Overweight 2335 (41.0) 15,133 (36.4)
 Obesity I 1264 (22.2) 5075 (12.2)
 Obesity II 330 (5.8) 1114 (2.7)
 Obesity III 133 (2.3) 293 (0.7)
 Dyslipidemia (%) 2686 (47.2) 12,636 (30.4) < 0.001
 CVD/CKD (%) 1495 (26.3) 4613 (11.1) < 0.001
10-years CV risk (%) < 0.001
 ≤ 2% 0 (0.0) 29,269 (70.6)
 3–9% 4155 (72.9) 7640 (18.4)
 ≥ 10% 1540 (27.1) 4613 (11.0)
 Familiar history of CVD (%) 2394 (42.0) 15,534 (37.4) < 0.001
 Salt use (%) 1436 (25.2) 11,124 (26.8) 0.012
 Fruits/vegetables use (%) 4504 (79.1) 33,665 (81.1) < 0.001
 Physical activity (%) 2397 (42.1) 19,254 (46.4) < 0.001
 Cigarette smoking (%) 1122 (19.7) 8420 (20.3) 0.318
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reported making less use of salt than the counterpart. No 
difference in diastolic BP and smoking habits was recorded 
by diabetic status.
3.2  Hypertension Prevalence, Awareness, 
Treatment, and Control
Hypertension prevalence, awareness, treatment, and control 
rates by diabetic status are summarized in Table 2. Hyper-
tension prevalence was 80% (N = 4556) among diabetic 
individuals and 54.7% (N = 22,733) among nondiabetics 
(p < 0.001). The age- and gender-adjusted OR (95% CI) for 
concomitant diabetes and hypertension was 2.28 (95% CI 
2.12–2.46; p < 0.001).
Awareness of hypertension was 85.6% (95% CI 
84.6–86.6; p < 0.001) in diabetic individuals and 77.3% 
(95% CI 76.8–77.9; p < 0.001) in nondiabetics. The likeli-
hood estimate for the difference between groups was 8.3% 
(95% CI 7.2–9.5; p < 0.001).
Among those with prevalent hypertension, 3910 individu-
als with diabetes and 17446 of nondiabetics reported using 
antihypertensive medications, with hypertension treatment 
rates of 85.8% (95% CI 84.8–86.8; p < 0.001) and 76.7% 
(95% CI 76.2–77.3; p < 0.001), respectively. The likelihood 
estimate for the difference between groups was 9.1% (95% 
CI 7.9–10.2; p < 0.001).
Among those with treated hypertension, 994 individu-
als with diabetes and 5366 of nondiabetics had controlled 
hypertension according to the 2017 ACC/AHA hypertension 
guidelines, with hypertension control rates of 25.4% (95% 
CI 24.1–26.8; p < 0.001) and 30.8% (95% CI 30.1–31.4; 
p < 0.001), respectively. The likelihood estimate for the dif-
ference between groups was -5.3% (95% CI − 6.9 to − 3.8; 
p < 0.001). Using the more recent 2018 ESC/ESH hyperten-
sion guidelines, 1410 individuals with diabetes and 6901 of 
nondiabetics had controlled hypertension, with hypertension 
control rates of 36.1% (95% CI 34.6–37.6; p < 0.001) and 
39.6% (95% CI 38.8–40.3; p < 0.001), respectively. The like-
lihood estimate for the difference between groups was -3.5% 
(95% CI − 5.2 to − 1.8; p < 0.001).
The prevalence of optimal and normal BP among diabetic 
individuals taking or not taking antihypertensive medica-
tions was lower compared with the same strata of nondiabet-
ics (Table 3). Conversely, the prevalence of isolated systolic 
hypertension among diabetic individuals taking or not taking 
antihypertensive medications was higher compared with the 
same strata of nondiabetics (Table 3).
Features associated with uncontrolled hypertension were 
male gender (OR 1.64, 95% CI 1.57–1.70, p < 0.001), ciga-
rette smoking (OR 1.34, 95% CI 1.27–1.40; p < 0.001), self-
reported diabetes (OR 1.23, 95% CI 1.15–1.31, p < 0.001), 
use of salt (OR 1.09, 95% CI 1.04–1.14; p < 0.001), non-use 
of fruits/vegetables (OR 1.09, 95% CI 1.03–1.14, p = 0.001), 
BMI (OR 1.07, 95% CI 1.07–1.08, p < 0.001), physical inac-
tivity (OR 1.04, 95% CI 1.00–1.09; p = 0.027), and age (OR 
1.03, 95% CI 1.02–1.03; p < 0.001) (Fig. 1).
4  Discussion
Real-world data from more than 47000 participants in an 
Italian nationwide epidemiological survey on common 
cardiovascular risk factors indicate that individuals with 
self-reported diabetes had more than double the risk of 
comorbid hypertension, as well as higher rates of hyperten-
sion awareness and treatment, compared with nondiabetics. 
Nevertheless, hypertension control rates remained largely 
unsatisfactory, especially among individuals with diabe-
tes. In this subset, in fact, only about one out of four indi-
viduals reached the BP target of < 130/80 mmHg. Besides 
diabetes and nonmodifiable demographic features, several 
self-reported modifiable traits were associated with uncon-
trolled hypertension, including cigarette smoking, excessive 
use of salt, poor consumption of greens, sedentary lifestyle, 
and excess body weight. Thus, improving clinical care of 
individuals with hypertension largely requires changes in 
lifestyle habits.
Besides sharing common contributors, including 
overweight, unhealthy lifestyle, and ageing, hyperten-
sion and diabetes mellitus are also strictly linked from a 
Table 2  Rates of hypertension 
prevalence, awareness, 
treatment, and control by 
diabetic status.
ACC/AHA American College of Cardiology/American Heart Association,ESC/ESH European Society of 
Cardiology/European Society of Hypertension
Diabetic participants 
(N = 5,695) (%)
Nondiabetic participants 
(N = 41,522) (%)
p value
Prevalence 80.0 54.7 < 0.001
Awareness 85.6 77.3 < 0.001
Treatment 85.8 76.7 < 0.001
Control
 2017 ACC/AHA guidelines 25.4 30.8 < 0.001
 2018 ESC/ESH guidelines 36.1 39.6 < 0.001
305 Real-World Hypertension Prevalence, Awareness, Treatment, and Control in Adult Diabetic Individuals 
pathophysiological point of view [17]. Insulin resistance, 
a common feature of both prediabetes and prehypertension 
[18], is associated with sodium and fluid retention. Insulin 
signaling can also modulate the vascular tone [19]. Other 
factors involved in the pathogenesis of both conditions 
include inappropriate activation of the renin-angiotensin-
aldosterone system, sympathetic imbalance, oxidative stress, 
inflammation, and dysfunctional immune response [17, 20]. 
Furthermore, some antihypertensive drugs (e.g. thiazide diu-
retics) can exert unfavorable effects on the glyco-insulinemic 
profile [21]; in parallel, the use of certain antidiabetic medi-
cations can induce sodium and water retention, with conse-
quent hemodynamic effects [22, 23].
The prevalence of hypertension by diabetic status and the 
risk of comorbid hypertension in the presence of diabetes 
that we described are similar in magnitude to those observed 
in a contemporary (2017-2018) cycle of the National Health 
and Nutrition Examination Survey (NHANES) [24]. Hyper-
tension control rates among NHANES nondiabetic individu-
als (39.01%, 95% CI 33.68–44.60) were comparable to our 
findings, and not dissimilar than those of NHANES diabetic 
individuals (40.39%, 95% CI 33.96–47.17) [24]. Another 
population-based cross-sectional survey found that treated 
hypertensives with diabetes were less likely to have con-
trolled BP (OR 0.38, 95% CI 0.25–0.58) compared with 
nondiabetics [25]. Altogether, real-world data indicate that 
attaining BP treatment goal remains a major challenge, espe-
cially when multiple cardiovascular risk factors coexist.
Although self-awareness of diabetes may be a motivation 
for positive interventions on modifiable risk factors, such as 
increasing physical activity, quitting smoking, and improv-
ing dietary habits, we did not observe differences in these 
features based on diabetic status, with the only exception 
of salt use. In parallel, the lack of hypertension awareness 
(14.4% among diabetic adults, 22.7% among nondiabet-
ics) might be one reason behind the high rates of untreated 
hypertension and unhealthy lifestyle habits in both groups. 
In this context, awareness-raising campaigns might increase 
the adhesion to pharmacological and nonpharmacological 
prevention strategies and contribute to improve diabetes 
care.
This study has limitations and strengths. As a cross-sec-
tional survey, it can only describe associations, and cause-
effect relationships cannot be inferred. A certain degree of 
selection bias, as well as the use of self-reported data, should 
be considered when interpreting the relative findings and 
might limit their generalizability. Conditions like white-coat 
Table 3  BP categories in survey 
participants with and without 
diabetes taking or not taking 
antihypertensive medications
All comparisons between the proportions of diabetic individuals taking or not taking antihypertensive med-
ications with the same proportions in nondiabetic individuals were significant (p < 0.05), except for grade 3 
hypertension. Optimal BP: < 120/80 mmHg; normal BP: 120–129 and/or 80–84 mmHg; high normal BP: 
130–139 and/or 85–89 mmHg; grade 1 hypertension: 140–159 and/or 90–99 mmHg; grade 2 hypertension: 
160–179 and/or 100–109 mmHg; grade 3 hypertension: ≥ 180 and/or ≥ 110 mmHg; and isolated systolic 
hypertension: ≥ 140 and < 90 mmHg
BP blood pressure, HTN hypertension, ISH isolated systolic hypertension
Diabetic participants (N = 5695) Nondiabetic participants (N = 41522)
On HTN meds 
(N = 3910)
Untreated (N = 1785) On HTN meds 
(N = 17446)
Untreated (N = 24076)
Optimal BP, N (%) 516 (13.2) 393 (22) 2837 (16.3) 8545 (35.5)
Normal BP, N (%) 617 (15.8) 330 (18.5) 3545 (20.3) 5412 (22.5)
High normal BP, N (%) 861 (22) 416 (23.3) 4175 (23.9) 4832 (20.1)
Grade 1 HTN, N (%) 332 (8.5) 166 (9.3) 1697 (9.7) 1797 (7.5)
Grade 2 HTN, N (%) 207 (5.3) 64 (3.6) 733 (4.2) 634 (2.6)
Grade 3 HTN, N (%) 6 (0.1) 3 (0.2) 21 (0.1) 34 (0.1)
ISH, N (%) 1371 (35.1) 413 (23.1) 4438 (25.4) 2822 (11.7)
Fig. 1  Forest plot of odds ratios (OR, 95% CI) for uncontrolled 
hypertension in association with selected demographic, clinical, and 
lifestyle features
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hypertension and masked hypertension cannot be detected in 
the setting of this survey. Data on type 1 and 2 diabetes could 
not be segregated. Finally, data on antihypertensive medi-
cations type and doses, treatment compliance, as well as on 
comorbidities [26, 27] or socioeconomic and cultural deter-
minants with possible impact on BP control were not avail-
able to our analysis. However, this survey was conducted on 
a large sample of non-institutionalized Italian population. A 
standardized protocol for BP measurement based on the use 
of automated devices was applied.
In conclusion, real-world data indicate that elevated hyper-
tension awareness and treatment rates in diabetic individuals 
do not translate into adequate BP control. Concomitant unfa-
vorable metabolic features and unhealthy lifestyle habits might 
at least in part explain this observation. Awareness-raising 
campaigns might contribute to the identification of individuals 
at greater need of care, thereby improving the targeted applica-
tion of pharmacological and nonpharmacological cardiovas-
cular prevention strategies.
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